Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

   
   

The present invention discloses compounds of formula I 1 wherein Ar, Z, m, n, p, R.sup.1 and R.sup.8 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

Die anwesende Erfindung gibt Mittel von Formel I 1, worin Ar, Z, m, n, p, R.sup.1 und R.sup.8 hierin definiert werden, die besagten Mittel frei, die Romanantagonisten für melanin-konzentrierendes Hormon (MCH) sind, sowie Methoden für das Vorbereiten solcher Mittel. In einer anderen Verkörperung gibt die Erfindung den pharmazeutischen Aufbau frei, der solche MCH Antagonisten sowie Methoden des Verwendens sie, um Korpulenz, metabolische Störungen zu behandeln enthält und ißt Störungen wie hyperphagia und Diabetes.

 
Web www.patentalert.com

< Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9,-trioxa-3-aza-cyclopent- a[a]naphthalene as 5-ht1a antagonists

< Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments

> Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes

> HMG-CoA reductase inhibitors and method

~ 00175